Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Aytu Biopharma (AYTU) Liabilities from Discontinued Operations (2024)

Aytu Biopharma has reported Liabilities from Discontinued Operations over the past 1 years, most recently at 557000.0 for Q2 2024.

Quarterly Liabilities from Discontinued Operations changed N/A to 557000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 557000.0 through Jun 2024, changed N/A year-over-year, with the annual reading at 557000.0 for FY2024, N/A changed from the prior year.
Liabilities from Discontinued Operations was 557000.0 for Q2 2024 at Aytu Biopharma.
Over five years, Liabilities from Discontinued Operations peaked at 557000.0 in Q2 2024 and troughed at 557000.0 in Q2 2024.